Enristomig Biosimilar Bispecific Single-Domain Antibody (PD-L1 × 4-1BB) for Research

Cat No.: GMP-Bios-INN-1184

Anti-PDL1/CD274 therapeutic antibody (Pre-made Enristomig biosimilar,Bispecific Single Domains (VH-VH'-G1(h-CH2-CH3) Dimer)) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Enristomig (development code INBRX-105) is a bispecific antibody targeting PD-L1 (CD274) and 4-1BB (TNFRSF9). It is developed by Elpiscience Biopharmaceuticals and Inhibrx. It is in Phase I clinical development.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1184-1mg 1mg
GMP-Bios-INN-1184-10mg 10mg
GMP-Bios-INN-1184-100mg 100mg
GMP-Bios-INN-1184-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Enristomig biosimilar, Bispecific Single Domains (VH-VH'-G1(h-CH2-CH3) Dimer), Anti-PDL1/CD274;TNFRSF9/CD137/4-1BB Antibody: Anti-PD-L1/CD274/Programmed cell death 1 ligand 1/PDCD1 ligand 1 therapeutic antibody
INN Name Enristomig
Target PDL1/CD274;TNFRSF9/CD137/4-1BB
Format Bispecific Single Domains (VH-VH'-G1(h-CH2-CH3) Dimer)
Derivation Humanized
Species Reactivity Human
CH1+2+3 Isotype G1;G1
VD LC na;na
Highest_Clin_Trial (Jan '20) Phase-I
Est. Status Discontinued
100% SI Structure None;None
99% SI Structure None;None
95-98% SI Structure None;None
Year Proposed 2023
Year Recommended 2024
Companies Elpiscience Biopharmaceuticals;Inhibrx
Conditions Approved na
Conditions Active na
Conditions Discontinued Hodgkin's disease;Non-Hodgkin's lymphoma;Solid tumours;Non-small cell lung cancer;Oesophageal cancer;Squamous cell cancer
Production na
Development Tech na